Claims for Patent: 10,953,106
✉ Email this page to a colleague
Summary for Patent: 10,953,106
| Title: | Antibodies |
| Abstract: | Antibodies having modified constant regions so as to permit conjugation of the antibody to a payload such as a therapeutic agent are described. Preferred antibodies include a mutation at light chain position 180 (positional numbering), most preferably the mutation is to a residue selected from C, K, Q, or a non-natural amino acid. Additional mutations may also be combined with a mutation at position 180; including one or more of light chain (LC) S208, LC S171, LC S182, LC A184, LC V191, LC S202, LC S203, LC T206, heavy chain (HC) S160, HC T190, HC S443, HC S447, HC S139, HC S168, HC V170, HC V176, HC T200, HC S445 according to a positional numbering convention. |
| Inventor(s): | Gomez De La Cuesta Ramon, Zurdo Jesús, Arnell Lars Arne Andreas, Ducry Laurent, Bonnafoux Laurence |
| Assignee: | LONZA LTD |
| Application Number: | US15550903 |
| Patent Claims: |
Details for Patent 10,953,106
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | December 22, 1994 | 10,953,106 | 2036-02-15 |
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | 10,953,106 | 2036-02-15 |
| Hoffmann-la Roche Inc. | ZENAPAX | daclizumab | Injection | 103749 | December 10, 1997 | 10,953,106 | 2036-02-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
